Conclusions and relevance
Adult vaccinations, particularly against herpes zoster, influenza, pneumococcus and Tdap, are associated with a lower risk of dementia. Vaccination strategies should be incorporated into public health initiatives for dementia prevention.
Paper: https://academic.oup.com/ageing/article/54/11/afaf331/8339764?login=false
Thereâs nothing in what you copied that suggests that. At most, we can conclude that we add about 1% per year, so in 10 years we could be ~55%. But thatâs highly speculative. If you read the Lancet report, they also list some areas that might be modifiable independent risk factors but are not yet confirmed (I think sleep is one of them, for instance). Even if you add those, Iâm not sure weâll go above 60%. And in any case, those interventions are already done by many people so at the population level we might not see more benefits.
Yes: look at the chart: Predicting Alzheimers & Dementia (and minimizing risk) - #1008 by RapAdmin
The progress in the 20y from 1984 to 2004 is more than from 2004 to 2024. So most likely 2024 to 2044 will be even less. This is a general rule that the last mile is the hardest to achieve.
Scary. Goose is already cooked.
A conceptual problem in classifying risk factors goes to derivation of cause. If, for example (only an illustration) a genetic variant determines or increases the probability of decreased folate assimilation, classifying it as a genetic cause with the implication or assertion that it is not modifiable is incorrect. In this example the intervention is simple and effective and the contribution to a causal chain is eliminated. Some genetic variants present as currently unmodifiable effects but many do not. Lp(a) was in that category until recently.
Intestinal interoceptive dysfunction drives age-associated cognitive decline
Risk factors for early-onset and late-onset dementia: a prospective cohort study
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00015-2/fulltext
A duo of drugs that boosts our glymphatic system, which clears waste from our brain, also improves the removal of proteins associated with the onset of Alzheimerâs disease
Our brain removes metabolic waste via the glymphatic system, a network of channels surrounding the blood vessels that pump waste fluid to the lymphatic system, where it is carried to the blood for disposal.
The glymphatic system is most active during deeper phases of sleep, when slow brain waves help push along waste fluid after it has been released from brain cells. But it becomes impaired with age, and especially during Alzheimerâs disease.
Researchers have previously found that dexmedetomidine, a drug commonly used as a sedative during medical procedures, boosts these brain waves in mice. It also improved the brainâs ability to clear waste fluid and slowed cognitive decline in mouse models of Alzheimerâs disease.
To explore dexmedetomidineâs effects in people, Paul Dagum at pharmaceutical company Applied Cognition in Redwood City, California, and his colleagues recruited 19 adults â aged 60, on average â who were deprived of sleep for one night in a lab. The morning after, the participants â who had no chronic medical conditions or brain-specific issues â provided blood samples to act as baseline measurements.
They were then given 4 hours while they received an infusion of dexmedetomidine. They also took a drug called midodrine, which treats low blood pressure, a common side effect of dexmedetomidine. When they woke, the participants provided another blood sample.
A few weeks later, the researchers repeated the experiment, but this time, the participants had a placebo pill and saline infusions. The researchers then compared the two post-nap blood samples, accounting for variations in the two baseline samples.
This revealed that taking dexmedetomidine and midodrine, which the company collectively calls ACX-02, cleared two amyloid and tau proteins that are particularly prone to misfolding and forming clumps more effectively than the placebo/saline intervention.
The team estimates that if ACX-02âs effect were sustained over several years, it could delay the onset or worsening of Alzheimerâs disease by about seven years, based on levels of misfolded amyloid that are typically seen in people who go on to develop the condition, says Dagum. âThat would be a significant, meaningful effect for those at risk,â adds team member Jeff Iliff at the University of Washington in Seattle.
Gu accepts that previous efforts to clear misfolded amyloid-beta and tau from the brains of people with Alzheimerâs disease have had limited benefits. Nevertheless, he adds that if the new approach is safe and effective, it could have a wide use. âIt could benefit people with other brain conditions caused by a build-up of misfolded proteins, such as Parkinsonâs,â he says. It might even be possible to develop a pill form of dexmedetomidine to treat attention lapses following sleep deprivation, says Iliff.
Read the full story: The brainâs cleaning system can be boosted to rid Alzheimerâs proteins (New Scientist)
I didnât interpret the chartâs trend as having much predictive power, because it only has three temporal data points. And the trendlines are so different depending on which age you look at
But i can see that extrapolation is temptingâŚ
Estimating at the raw data, and looking at say , â% with dementia aged 90to94â - this falls from 45% in 1984 to 25% in 2004 and 15% in 2024. Extrapolating could suggest 10% in 2044, 7.5% in 2064 etc ultimately plateauing to only 5%.
But thatâs relying quite a bit on a very limited trendline. And the historic deceleration may have a lot more to do with public health issues (accelerating processed food consumption, or inactivity or social isolation or inequality etc) than anything that should be applied to the modifiability of an individualâs risk
I would argue that accelerating progress in medicine and healthcare from AGI amd also the the increasing capital for research and development and the fact that we have so many âcluesâ as to where to investigate next will mean that we wont see this deceleration in practiceâŚ
As an example, ive just put my genome into claude.ai and it has generated reams of advice on bespoke preventative measures for preserving cognitive health. Most i was doing anyway, but several are novel and with decent logic behind them. For example my PEMT allele status means i dont effectively produce
phosphatidylcholine (along with a third if the population) - taking citicholine more regularly should have a marked impact on my dementia risk. Yet this would not be in the radar of either the general population or a typical doctor.
Besides the mechanical reasoning, is there clinical evidence in favor of that?
The Pre-Diagnostic Map: How Your Medical History Predicts the Velocity of Neurodegeneration
Neurodegenerative diseases like Alzheimerâs and Parkinsonâs are traditionally viewed through a categorical lensâbinary states of âhealthyâ or âdiagnosed.â A landmark study by Lian and colleagues, analyzed here by Nedelec and Corvol, shatters this simplistic model. By applying transformer-based AI to the electronic health records (EHR) of over 100,000 patients, researchers have mapped a complex, 15-year âprodromalâ period where the seeds of brain decay are visible long before the first tremor or memory lapse appears.
The investigation identifies five distinct subtypes for both Alzheimerâs and Parkinsonâs, characterized by unique clinical trajectories and comorbidity burdens. The âBig Ideaâ is a fundamental shift in perspective: neurodegeneration does not happen in isolation. Instead, it is the culmination of a decade-plus of systemic failures in metabolic, vascular, and psychiatric health.
Perhaps most striking is the discovery of âconvergent phenotypesâ. Patients with metabolic-inflammatory profilesâmarked by obesity, diabetes, and renal diseaseâfollow nearly identical, aggressive paths toward disability regardless of whether their primary diagnosis is Alzheimerâs or Parkinsonâs. This suggests that while genetics might load the gun by determining disease susceptibility, systemic factors like insulin resistance and neuroinflammation pull the trigger on the rate of progression.
The study also reveals a counterintuitive âdissociationâ between genetic risk and clinical severity. Some individuals with high polygenic risk scores follow a âclassicâ slow-burn trajectory, while those with lower genetic risk but high metabolic dysfunction suffer rapid, high-mortality outcomes. This underscores a critical reality for the longevity community: your âgenetic destinyâ is a poor predictor of how fast you will decline if your metabolic health is compromised.
Aggressive Metabolic Management: The âMetabolic-inflammatoryâ subtype (Cluster 4) across both diseases exhibits the most aggressive clinical decline and highest mortality. Managing biomarkers associated with diabetes, obesity, and renal health is not just for heart health; it is the primary lever for slowing neurodegenerative velocity. [Confidence: High]
The 15-Year Window: Prodromal signalsâincluding depression, hearing loss, sleep disturbances, and constipationâprecede motor and cognitive symptoms by up to 15 years. Treating these âunrelatedâ comorbidities early may alter the eventual disease trajectory. [Confidence: Medium]
Modifiable Risk Supremacy: Up to 45% of dementia cases may be attributable to modifiable risk factors. Interventions targeting insulin signaling and systemic inflammation (e.g., GLP-1 agonists, SGLT2 inhibitors, or senolytics) could potentially benefit patients across different diagnostic categories by stabilizing the âprogression environmentâ of the brain. [Confidence: Medium]
For decades, the medical community treated hearing loss (HL) and Alzheimerâs disease (AD) as distinct consequences of the aging processâone a matter of sensory degradation, the other a catastrophic cognitive collapse. However, a comprehensive 20-year retrospective analysis published in Ageing Research Reviews (2025) confirms that these two conditions are biologically and mechanistically entwined. Analyzing 349 core studies from 2004 to 2024, researchers have mapped a âclosed-loopâ relationship where auditory decline not only signals early neurodegeneration but actively accelerates it.
The study identifies a critical distinction between peripheral hearing loss (PHL) âstemming from the earâs hardwareâand central hearing loss (CHL) , which involves the brainâs processing centers. PHL acts as a âgatewayâ to cognitive decline primarily through sensory deprivation; when the brain is starved of auditory input, it undergoes structural atrophy due to disuse and increased social isolation. Conversely, CHL shares a direct molecular âhandshakeâ with Alzheimerâs, characterized by synaptic degeneration and neuroinflammation in the same regions responsible for memory, such as the hippocampus.
Bioinformatic mapping revealed 2,747 shared genes between the two conditions. These genes cluster around three primary axes: the PI3K-Akt signaling pathway (critical for neuronal survival), the AGE-RAGE axis (a driver of inflammation), and canonical Alzheimerâs pathways. The research suggests that hearing impairment, particularly central auditory dysfunction, may serve as one of the earliest detectable biomarkers for AD, often appearing before clinical memory loss. As global populations age, this meta-analysis underscores that hearing health is not a secondary quality-of-life issue but a frontline defense in the fight against dementia.
Prioritize Subtype Diagnosis: Distinguish between ear-level (peripheral) and brain-level (central) hearing issues. Central auditory processing deficits are more indicative of direct neurodegenerative risk.
Hearing as a Modifiable Risk Factor: Treat hearing loss as a primary, modifiable risk factor for dementia. Early intervention with hearing aids or cochlear implants may mitigate the âsensory deprivationâ pathway that leads to cortical atrophy.
Targeted Screening: Integrate auditory assessments into standard neurological exams for adults over 65, as hearing thresholds are strong prognostic indicators of future cognitive decline.
Molecular Synergy: Consider that compounds supporting the PI3K-Akt pathway (e.g., certain neuroprotectives) may simultaneously benefit both auditory longevity and cognitive resilience.
Yes, i was mainly highlighting it as an example of where we have âcluesâ as to other factors we can fix. But there is some evidence beyond the mechanics:
https://share.google/aimode/vkC1kxCzzLeQC6PCU
A note on using claude.ai with your genome. About half the recommendations were overstated and didnât stand up to scrutiny. Getting claude to check its own work is a quick fix
Website: https://strongermemory.org
This report provides a clinical and critical distillation of the StrongerMemory program, a non-pharmacological cognitive intervention developed by Rob Liebreich (CEO, Goodwin Living). The summary integrates the provided transcript with evidence from George Mason University and Tohoku University research.
The core thesis of the StrongerMemory program is that daily, low-anxiety engagement in three specific neuro-stimulatory tasksâreading aloud, handwriting, and rapid simple mathâcan stabilize or improve cognitive function in individuals experiencing Mild Cognitive Impairment (MCI) or subjective cognitive decline. Mechanistically, these tasks are designed to maximize blood flow and activation in the prefrontal cortex and hippocampus, regions primary to memory encoding and retrieval that often show reduced activation in aging populations Kawashima et al., 2012.
The program transitions cognitive health from a passive, pharmaceutical-dependent model to an active, habit-based âbrain exerciseâ regimen. Recent quasi-experimental data from George Mason University indicates significant statistical improvements in cognitive scoring for participants following a 12-week protocol Ihara et al., 2025. Critically, the intervention demonstrates a âtransfer effect,â where training in simple arithmetic and literacy improves non-targeted executive functions and processing speeds.
Furthermore, Phase II research suggests that while solitary practice is effective, the integration of social engagement(group reading/sessions) creates a synergistic effect, enhancing emotional well-being and longitudinal durability of the cognitive gains Kang et al., 2025. Field data from a three-year CMS-funded pilot involving 91 nursing homes reported that 76% of participants experienced perceived or actual cognitive stabilization, challenging the standard narrative of inevitable decline in institutional settings.
Brain-swooshing exercise could ward off dementia | Prof. Patrick Drew & Francesco Costanzo (via Penn State News and Research)
Gemini: Here is a summary of the video:
TL;DR: How Movement Protects the Brain
More data pointing to omega 3 supplementation being detrimental: Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn
